Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Epidermal growth factor receptor (EGFR) is one of the most commonly altered genes in human cancer by way of over-expression, amplification, and mutation. Targeted inhibition of EGFR activity suppresses signal transduction pathways which control tumor cell growth, proliferation, and resistance to apoptosis. Small molecule tyrosine kinase inhibitors and monoclonal antibodies are among the most common EGFR-targeting agents and have been used clinically for treating various malignancies. This review discusses the successes and challenges of targeting EGFR in human cancer. The genetic alterations of EGFR tend to occur more often in some solid tumors than others, as do the mechanisms of resistance to targeted inhibition. The clinical and basic science experiences with these agents thus far have important implications for the future of therapeutic targeting of EGFR.
Antibodies, Monoclonal, Antineoplastic Agents, Drug Resistance, Neoplasm, Humans, Molecular Targeted Therapy, Mutation, Neoplasms, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Signal Transduction
5-12
Wykosky, J
411e9851-1e7e-4548-b23a-d43f56437455
Fenton, TR
087260ba-f6a1-405a-85df-099d05810a84
Furnari, F
eb84de55-9ec1-480b-8424-11703ab8db3d
Cavenee, WK
e92aa948-8cc9-419f-a596-b36ed9ceeb09
1 January 2011
Wykosky, J
411e9851-1e7e-4548-b23a-d43f56437455
Fenton, TR
087260ba-f6a1-405a-85df-099d05810a84
Furnari, F
eb84de55-9ec1-480b-8424-11703ab8db3d
Cavenee, WK
e92aa948-8cc9-419f-a596-b36ed9ceeb09
Wykosky, J, Fenton, TR, Furnari, F and Cavenee, WK
(2011)
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
Chinese Journal of Cancer, 30 (1), .
(doi:10.5732/cjc.010.10542).
Abstract
Epidermal growth factor receptor (EGFR) is one of the most commonly altered genes in human cancer by way of over-expression, amplification, and mutation. Targeted inhibition of EGFR activity suppresses signal transduction pathways which control tumor cell growth, proliferation, and resistance to apoptosis. Small molecule tyrosine kinase inhibitors and monoclonal antibodies are among the most common EGFR-targeting agents and have been used clinically for treating various malignancies. This review discusses the successes and challenges of targeting EGFR in human cancer. The genetic alterations of EGFR tend to occur more often in some solid tumors than others, as do the mechanisms of resistance to targeted inhibition. The clinical and basic science experiences with these agents thus far have important implications for the future of therapeutic targeting of EGFR.
This record has no associated files available for download.
More information
Published date: 1 January 2011
Keywords:
Antibodies, Monoclonal, Antineoplastic Agents, Drug Resistance, Neoplasm, Humans, Molecular Targeted Therapy, Mutation, Neoplasms, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Signal Transduction
Identifiers
Local EPrints ID: 453958
URI: http://eprints.soton.ac.uk/id/eprint/453958
PURE UUID: a496588a-a012-425d-9617-63f80b301907
Catalogue record
Date deposited: 26 Jan 2022 17:49
Last modified: 17 Mar 2024 04:11
Export record
Altmetrics
Contributors
Author:
J Wykosky
Author:
F Furnari
Author:
WK Cavenee
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
